An overview on clinical, pathological and molecular features of lung metastases from colorectal cancer

Procaccio, Letizia; Bergamo, Francesca; Manai, Chiara; Antonio, Veronica Di; Fassan, Matteo; Zagonel, Vittorina; Loupakis, Fotios

doi:10.1080/17476348.2019.1620605

Cited by 8 publications

(7 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 As with any other cancer, the development, progression, and metastasis of lung cancer is a very complex process, involving multiple gene and cellular pathway aberrations. 24 The DEGs between NSCLC and normal tissue may be the core functional genes that promote the occurrence and development of NSCLC. 25,26 To improve the diagnosis and treatment of NSCLC, it is important to identify these DEGs and understand their role in the molecular mechanisms of NSCLC.…”

Section: Discussionmentioning

confidence: 99%

Bioinformatics analysis reveals 6 key biomarkers associated with non-small-cell lung cancer

et al. 2019

View full text Add to dashboard Cite

Objective Non-small-cell lung cancer (NSCLC) accounts for >85% of lung cancers, and its incidence is increasing. We explored expression differences between NSCLC and normal cells and predicted potential target sites for detection and diagnosis of NSCLC. Methods Three microarray datasets from the Gene Expression Omnibus database were analyzed using GEO2R. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis were conducted. Then, the String database, Cytoscape, and MCODE plug-in were used to construct a protein–protein interaction (PPI) network and screen hub genes. Overall and disease-free survival of hub genes were analyzed using Kaplan-Meier curves, and the relationship between expression patterns of target genes and tumor grades were analyzed and validated. Gene set enrichment analysis and receiver operating characteristic curves were used to verify enrichment pathways and diagnostic performance of hub genes. Results In total, 293 differentially expressed genes were identified and mainly enriched in cell cycle, ECM–receptor interaction, and malaria. In the PPI network, 36 hub genes were identified, of which 6 were found to play significant roles in carcinogenesis of NSCLC: CDC20, ECT2, KIF20A, MKI67, TPX2, and TYMS. Conclusion The identified target genes can be used as biomarkers for the detection and diagnosis of NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Bioinformatics analysis reveals 6 key biomarkers associated with non-small-cell lung cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The lungs are the second most common site for metachronous metastases. Although the incidence and pattern of lung metastases in the modern era of multimodal treatment are less known, recent studies point at an incidence between 5% and 10% 16–18 . During the last two decades, surgery has become more common in the treatment of lung metastases even if its relative value is questioned, 19–22 as lung metastases respond to chemotherapy 15,23 .…”

Section: Introductionmentioning

confidence: 99%

“…Although the incidence and pattern of lung metastases in the modern era of multimodal treatment are less known, recent studies point at an incidence between 5% and 10%. [16][17][18] During the last two decades, surgery has become more common in the treatment of lung metastases even if its relative value is questioned, [19][20][21][22] as lung metastases respond to chemotherapy. 15,23 Nevertheless, 5-year overall survival (OS) rates between 40% and 68% have been reported following metastasectomy of lung metastases, [24][25][26][27] suggesting that lung resection might have curative potential.…”

Section: Introductionmentioning

confidence: 99%

Treatment and survival of patients with metachronous colorectal lung metastases

Hansdotter

Scherman

Nikberg

et al. 2023

Journal of Surgical Oncology

View full text Add to dashboard Cite

Introduction The lungs are the second most common site for metachronous metastases in colorectal cancer. No treatment algorithm is established, and the role of adjuvant chemotherapy is unclear. This study aimed to map pulmonary recurrences in a modern multimodal treated population, and to evaluate survival depending on management. Methods Retrospective study based on the COLOFOL‐trial population of 2442 patients, radically resected for colorectal cancer stage II–III. All recurrences within 5 years were identified and medical records were scrutinized. Results Of 165 (6.8%) patients developing lung metastases as first recurrence, 89 (54%) were confined to the lungs. Potentially curative treatment was possible in 62 (37%) cases, of which 33 with surgery only and 29 with surgery and chemotherapy combined. The 5‐year overall survival (5‐year OS) for all lung recurrences was 28%. In patients treated with chemotherapy only the 5‐year OS was 7.5%, compared with 55% in patients treated with surgery, and 72% when surgery was combined with chemotherapy. Hazard ratio for mortality was 2.9 (95% confidence interval 1.40–6.10) for chemotherapy only compared to surgery. Conclusion A high proportion of metachronous lung metastases after colorectal surgery were possible to resect, yielding good survival. The combination of surgery and chemotherapy might be advantageous for survival.

show abstract

“…1 The incidence and mortality of CRC do not reduce significantly, even with effective cancer screening measurements and great advancements in cancer treatment. 2,3 Surgical resection with adjuvant chemotherapy is effective for early stage CRC treatment, nevertheless, there is no effective therapy for advanced stage patients, especially for those with metastatic cancer. 4,5 Therefore, it is urgent to find more effective and safe therapies for the prevention and treatment of CRC.…”

Section: Introductionmentioning

confidence: 99%

Fisetin Inhibits Trypsin Activity and Suppresses the Growth of Colorectal Cancer in Vitro and in Vivo

Wang

YANG

et al. 2022

Natural Product Communications

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a malignant tumor with high incidence and bad prognosis. Therapies, which are more safe and effective, are urgently needed. Trypsin is proved to be crucial to cancer proliferation and migration, therefore, it is possible to control cancers by modulating its activity. Fisetin is a flavone with trypsin inhibition properties that was screened from more than 45 compounds derived from traditional Chinese medicine (TCM). However, the effects and mechanisms of fisetin on CRC have not been well investigated. In this study, we evaluated the effects of fisetin on 2 different CRC cell lines. Fisetin remarkably inhibited CRC cell proliferation and migration, as well as induced cell apoptosis and Go/G1 phase arrest in a dose-dependent manner. Mechanistic studies revealed that these effects were mediated partially through signaling pathways involving cell cycle regulators p21, p27, cyclinD1, and NF kappa B (NF-κB) p65. Administration of fisetin also significantly suppressed the tumor growth in tumor-bearing NOD/Shi-scid-IL2R gamma (null) (NOG) mice that had been inoculated with human HCT116 cells. Fisetin at the given dosage did not induce significant acute or chronic toxicity in rats. These data provide a potential therapeutic strategy for CRC.

show abstract

An overview on clinical, pathological and molecular features of lung metastases from colorectal cancer

Cited by 8 publications

References 76 publications

Bioinformatics analysis reveals 6 key biomarkers associated with non-small-cell lung cancer

Bioinformatics analysis reveals 6 key biomarkers associated with non-small-cell lung cancer

Treatment and survival of patients with metachronous colorectal lung metastases

Fisetin Inhibits Trypsin Activity and Suppresses the Growth of Colorectal Cancer in Vitro and in Vivo

Contact Info

Product

Resources

About